Work

2700 Final results of ARIEL2 (Part 1): A phase 2 trial to prospectively identify ovarian cancer (OC) responders to rucaparib using tumor genetic analysis

Year: 2015

Type: article

Source: European Journal of Cancer

DOI: 10.1016/s0959-8049(15)30050-2

Authors: R. Kristeleit, E. Swisher, A. Oza, R.L. Coleman, C. Scott, G. Konecny, A. Tinker, D.M. O'Malley, J. Brenton, K. Bell-McGuinn, A. Oaknin, A. Leary, K.K. Lin, M. Raponi, H. Giordano, L. Maloney, S. Goble, R. Yelensky, I. McNeish

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2345701447

FWCI: 2.731

Cites:

Cited by: 23

Related to: 10